Kleiner Perkins Caufield & Byers is expected to benefit from the swine flu outbreak because of its investments in pandemic and biodefense companies, including BioCryst Pharmaceuticals and Novavax, according to Thomson Reuters Private Equity Week. While BioCryst said its vaccine is still in clinical trials, Novavax's CEO expressed confidence the company can create a vaccine for the virus in 12 weeks.

Full Story:

Related Summaries